Broad Agency Announcement

Terra Drone's Group Company, Unifly, Successfully Completes Groundbreaking UTM Cybersecurity Model Project in Partnership with FAA

Retrieved on: 
Wednesday, December 27, 2023

In partnership with the Rhea Group and NY UAS Test Site (NYUASTS), the objective and purpose of the project was to refine a UTM cybersecurity model, including the requirements and certification scheme, and to validate the model in an operational environment.

Key Points: 
  • In partnership with the Rhea Group and NY UAS Test Site (NYUASTS), the objective and purpose of the project was to refine a UTM cybersecurity model, including the requirements and certification scheme, and to validate the model in an operational environment.
  • As drone use continues to rise, it's vital to develop specific cybersecurity measures for UTM to ensure airspace safety and security.
  • Although cybersecurity is unanimously recognized as a critical safety concern, UTM cybersecurity has only been partially explored to this date.
  • In the initial phase of the project, interviews were conducted with the following stakeholders from the UTM ecosystem:
    During the interviews, the concept of a unified UTM cybersecurity model was presented.

EverGlade Consulting Funding Alert: DTRA BAA Outlines New Opportunity to Identify and Counter Weapons of Mass Destruction (WMD) through the Strategic Trends Research Initiative

Retrieved on: 
Monday, September 25, 2023

CHARLESTON, S.C., Sept. 25, 2023 /PRNewswire/ -- The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined as nuclear, chemical, and/or biological weapons. DTRA's Strategic Integration Directorate (SI) leads in generating insights and outlining future threats, focusing on strategic dialogues and research studies through STRI, enabling a profound understanding of emerging threats and fostering relationships with allies and non-traditional partners to counter WMD-related security challenges.

Key Points: 
  • CHARLESTON, S.C., Sept. 25, 2023 /PRNewswire/ -- The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined as nuclear, chemical, and/or biological weapons.
  • The amendment delineates two thrust areas: Thrust Area 1 emphasizes WMD-relevant strategic dialogues under the "Chatham House Rule," facilitating confidential discussions to gain strategic insights and strengthen partnerships.
  • DTRA will conduct a virtual Research Topic Information Session on October 4, 2023, allowing participants to inquire about research priorities and other BAA-related topics.
  • EverGlade Consulting is a national consulting firm helping clients navigate the federal landscape.

Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach

Retrieved on: 
Friday, August 11, 2023

PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.

Key Points: 
  • PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.
  • The results of the preclinical assessment initiative are now published in "Drug Discovery Today" titled, "Immunogenicity Risk Assessment of Synthetic Peptide Drugs and Their Impurities."
  • Throughout the program, EpiVax adapted in silico and in vitro immunogenicity risk assessment methods, previously leveraged for vaccine and biologics assessment, to evaluate the immunogenicity of generic drug impurities.
  • Since 2018, EpiVax's scientists have garnered extensive experience in supporting drug manufacturers with immunogenicity assessments for ANDA submissions to various global regulatory agencies.

Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach

Retrieved on: 
Friday, August 11, 2023

PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.

Key Points: 
  • PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.
  • The results of the preclinical assessment initiative are now published in "Drug Discovery Today" titled, "Immunogenicity Risk Assessment of Synthetic Peptide Drugs and Their Impurities."
  • Throughout the program, EpiVax adapted in silico and in vitro immunogenicity risk assessment methods, previously leveraged for vaccine and biologics assessment, to evaluate the immunogenicity of generic drug impurities.
  • Since 2018, EpiVax's scientists have garnered extensive experience in supporting drug manufacturers with immunogenicity assessments for ANDA submissions to various global regulatory agencies.

Xplore Awarded National Reconnaissance Office contract for Commercial Hyperspectral Capabilities

Retrieved on: 
Wednesday, March 22, 2023

REDMOND, Wash., March 22, 2023 /PRNewswire-PRWeb/ -- Xplore Inc., a space company providing commercial data today announced that the National Reconnaissance Office (NRO) has awarded Xplore a contract to evaluate the company's Commercial Hyperspectral Capabilities (CHC) under the agency's Broad Agency Announcement (BAA) for its Strategic Commercial Enhancements effort. This award represents the first stage of a process to assess the potential of Xplore supplying commercial hyperspectral data to the NRO.

Key Points: 
  • REDMOND, Wash., March 22, 2023 /PRNewswire-PRWeb/ -- Xplore Inc., a space company providing commercial data today announced that the National Reconnaissance Office (NRO) has awarded Xplore a contract to evaluate the company's Commercial Hyperspectral Capabilities (CHC) under the agency's Broad Agency Announcement (BAA) for its Strategic Commercial Enhancements effort.
  • This award represents the first stage of a process to assess the potential of Xplore supplying commercial hyperspectral data to the NRO.
  • "Xplore is honored to be selected as an NRO mission partner for this new and important national capability," said Lisa Rich, Founder and COO of Xplore.
  • Xplore's inaugural launch will include novel hyperspectral capabilities that provide a level of taskability and tailorability not present in single-sensor satellites.

Helix & CDC to Study the Role of Human Genetics in Vaccine Effectiveness

Retrieved on: 
Wednesday, January 4, 2023

SAN MATEO, Calif., Jan. 4, 2023 /PRNewswire/ -- Helix, the leading population genomics and viral surveillance company in the nation, today announced a new Broad Agency Announcement (BAA) contract awarded by the Centers for Disease Control and Prevention (CDC) to better understand the role of human genetics in vaccine effectiveness particularly across SARS-CoV-2 variants. This new agreement extends the Company's viral sequencing leadership and further builds upon Helix's successful public-private partnership with the CDC.

Key Points: 
  • This new agreement extends the Company's viral sequencing leadership and further builds upon Helix's successful public-private partnership with the CDC.
  • "The new research conducted by Helix and CDC will uncover meaningful information to better understand and inform what we know of long COVID and other adverse effects.
  • The study will examine up to 10,000 individuals who have had breakthrough infections and severe COVID outcomes, despite being fully vaccinated.
  • Currently, few studies formally address the host genetics of vaccine effectiveness, or the interplay between host and viral genetic variation in the context of breakthrough infections.

Helix & CDC Expand Partnership to Build First Ever Pan-Respiratory Viral Surveillance Program

Retrieved on: 
Thursday, December 15, 2022

SAN MATEO, Calif., Dec. 15, 2022 /PRNewswire/ -- Helix, the leading population genomics and viral surveillance company in the nation, today announced a new Broad Agency Announcement (BAA) contract awarded by the Centers for Disease Control and Prevention (CDC) to build a pan-respiratory viral surveillance program that standardizes linkage of viral sequencing data to key clinical and demographic data across a multi-site network. As part of the program, Helix will be partnering with HealthPartners, an integrated health care organization based in Bloomington, Minnesota of more than 1,800 physicians that serves more than 1.2 million patients, and Providence, a Renton, Washington-headquartered health care system of 25,000 physicians serving nearly 2 million covered lives across seven states with 28.1 million patient visits annually. This new agreement builds upon the partnership between Helix and the CDC and brings in health systems as critical partners to prepare the nation for the next public health emergency and ensure that COVID-19 never happens again.

Key Points: 
  • Helix was awarded $5 million from the CDC to build a pan-respiratory viral surveillance "early warning" program that will identify and track over 30 respiratory viral variants (including SARS-CoV-2, influenza, RSV, rhinovirus, etc.)
  • along with de-identified EHR data, for up to 16,000 samples over one year using the Company's proprietary Viral Sequencing Respiratory Panel.
  • "The CDC and Helix, working with health care systems, are leading the way to monitor viral outbreaks and improve national pandemic readiness."
  • Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics.

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

Retrieved on: 
Thursday, November 17, 2022

For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.

Key Points: 
  • For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
  • It is extremely exciting to see BARDA announce increased emphasis on fighting dangerous fungal pathogens, said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS.
  • Ibrexafungerp, with its promising activity against multiple drug resistant and often-deadly fungal infections, has enormous potential to benefit patients with severe fungal disease and limited treatment options.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

HawkEye 360 Awarded Radio Frequency Contract by the National Reconnaissance Office

Retrieved on: 
Wednesday, September 28, 2022

HERNDON, Va., Sept. 28, 2022 /PRNewswire/ -- HawkEye 360 Inc., the world's leading commercial provider of space-based radio frequency (RF) data and analytics, announced today it has been awarded a contract from the NRO's Commercial Systems Program Office (CSPO).  The contract will assess, mature, integrate, and operationalize commercial RF intelligence into the NRO's integrated overhead architecture to support warfighters, the intelligence community, and policymakers. The program represents a partnership between the NRO and HawkEye 360 to explore near- and long-term high-impact capabilities commercial RF can deliver.

Key Points: 
  • HERNDON, Va., Sept. 28, 2022 /PRNewswire/ -- HawkEye 360 Inc., the world's leading commercial provider of space-based radio frequency (RF) data and analytics, announced today it has been awarded a contract from the NRO's Commercial Systems Program Office (CSPO).
  • The program represents a partnership between the NRO and HawkEye 360 to explore near- and long-term high-impact capabilities commercial RF can deliver.
  • HawkEye 360 operates a growing constellation of satellites which detects, characterizes, and geolocates radio frequency signals from a broad range of emitters used for communication, navigation, and security.
  • HawkEye 360 is delivering a revolutionary source of global knowledge based on radio frequency (RF) geospatial intelligence to those working to make the world a safer place.

Spire Global Awarded $4 Million NOAA Contract to Deliver Hyperspectral Microwave Sensing Payload

Retrieved on: 
Monday, September 26, 2022

The original objective of NOAAs BAA was to develop a HyMS prototype in an airborne or balloon-based platform.

Key Points: 
  • The original objective of NOAAs BAA was to develop a HyMS prototype in an airborne or balloon-based platform.
  • The HyMS instrument is a new, advanced millimeter wave technology that delivers microwave sounding information to measure atmospheric moisture.
  • In this era of extreme weather, the need to leverage data from space to deliver more accurate weather forecasts has never been more critical.
  • Spire has been awarded a total of four NOAA contracts in FY22, valued at $23.6 Million.